Therapeutic effects and safety of ternbinafine vaginal effervescent tablets combined with fluconazole in patients with recurrent vulvovaginal candidiasis
FANG Jie, WANG Xin, Shang Lixin, LIU Jingchao
Department of Obstetrics and Gynecology, Beijing Command General Hospital of PLA, Beijing 100700, China
Abstract：Objective To study the efficacy and safety of ternbinafine vaginal effervescent tablets combined with fluconazole in the treatment of recurrent vulvovaginal candidiasis (RVVC). Methods Totally 228 patients with RVVC were randomly divided into the control group and the study group with 114 cases in each. The control group was treated with fluconazole 150 mg orally for a total of 3 times per 3 days. The study group was given the same drug as the control group and additionally treated with ternbinafine vaginal effervescent tablets 50 mg every day (the treatment course was 14 days). The clinical effect, effective rate and the incidence of adverse reactions in the two groups were compared. Results The total cure rate in the study group was 92.1%, higher than that in the control group ( 81.6% ), and the difference was statistically significant (χ2=5.53, P=0.02 ). The clinical symptoms in the two groups were significantly improved after the treatment (P<0.05). The clinical symptom of vaginal secretion and vaginal congestion improved significantly in the study group (P<0.05). The adverse reactions in the two groups(control group 13.2%, study group 14.9%)had no significant difference. Conclusions The ternbinafine vaginal effervescent tablets can raise the cure rate of RVVC. No obvious adverse effects were observed about ternbinafine vaginal effervescent tablets.
2015, Vol. 26 
